Literature DB >> 18202454

Homing of radiolabelled recombinant interleukin-2 activated natural killer cells and their efficacy in adoptive immunotherapy against murine fibrosarcoma.

Anuradha Rai1, Ashim K Chakravarty.   

Abstract

Natural killer (NK) cells are spontaneously cytotoxic against tumour target cells. Their number was found to be four times more in the spleen of tumour-bearing Swiss albino mice. After activation with recombinant interleukin-2 (rIL-2), NK cells were tested and found to seek out the tumour site when injected intravenously in tumour-bearing mice. Their potential for fighting tumours in vivo was further seen following adoptive transfer of rIL-2 activated NK (A-NK) cells in tumour-bearing mice. After surgical removal of tumour load, adoptive transfer of A-NK cells inhibited tumour recurrence in 92.3%cases, thereby suggesting the use of this protocol for therapeutic purposes to obtain a better outcome.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18202454     DOI: 10.1007/s12038-007-0139-4

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  21 in total

1.  Activation of the complement system during immunotherapy with recombinant IL-2. Relation to the development of side effects.

Authors:  L G Thijs; C E Hack; R J Strack van Schijndel; J H Nuijens; G J Wolbink; A J Eerenberg-Belmer; H Van der Vall; J Wagstaff
Journal:  J Immunol       Date:  1990-03-15       Impact factor: 5.422

2.  Interleukin-2 augments natural killer cell activity.

Authors:  C S Henney; K Kuribayashi; D E Kern; S Gillis
Journal:  Nature       Date:  1981-05-28       Impact factor: 49.962

Review 3.  The role of natural killer cells in immune surveillance of cancer.

Authors:  T L Whiteside; R B Herberman
Journal:  Curr Opin Immunol       Date:  1995-10       Impact factor: 7.486

4.  "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype.

Authors:  R Kiessling; E Klein; H Wigzell
Journal:  Eur J Immunol       Date:  1975-02       Impact factor: 5.532

Review 5.  Interleukin-2 toxicity.

Authors:  J P Siegel; R K Puri
Journal:  J Clin Oncol       Date:  1991-04       Impact factor: 44.544

Review 6.  NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity.

Authors:  Per A Albertsson; Per H Basse; Marianne Hokland; Ronald H Goldfarb; J Fred Nagelkerke; Ulf Nannmark; Peter J K Kuppen
Journal:  Trends Immunol       Date:  2003-11       Impact factor: 16.687

7.  Role of NK cells in the control of metastatic spread and growth of tumor cells in mice.

Authors:  E Gorelik; R H Wiltrout; K Okumura; S Habu; R B Herberman
Journal:  Int J Cancer       Date:  1982-07-15       Impact factor: 7.396

8.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Authors:  M T Lotze; Y L Matory; S E Ettinghausen; A A Rayner; S O Sharrow; C A Seipp; M C Custer; S A Rosenberg
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

9.  Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

Authors:  K A Margolin; A A Rayner; M J Hawkins; M B Atkins; J P Dutcher; R I Fisher; G R Weiss; J H Doroshow; H S Jaffe; M Roper
Journal:  J Clin Oncol       Date:  1989-04       Impact factor: 44.544

Review 10.  Interleukin-2.

Authors:  K A Smith
Journal:  Curr Opin Immunol       Date:  1992-06       Impact factor: 7.486

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.